Print this page
Saturday, 30 August 2014 14:14

Anticoagulation news items. Week commencing 25th August 2014

Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a European consensus document

European Heart Journal
This updated joint consensus document discusses the optimal antithrombotic therapy management in AF patients presenting with ACS and/or undergoing percutaneous coronary or valve interventions and provides recommendations for use in clinical practice.


Aspirin for the Prevention of Recurrent Venous Thromboembolism: The INSPIRE Collaboration

This individual-patient-data analysis of the WARFASA and ASPIRE trials found low-dose aspirin for extended treatment of VTE reduced recurrent VTE (5.1% vs. 7.5%/yr with placebo) and major vascular events (5.7% vs. 8.7%/yr). The rate of major bleeding was low (0.5% vs. 0.4%/yr).


Symptomatic Hepatocellular Liver Injury With Hyperbilirubinemia in Two Patients Treated With Rivaroxaban

JAMA Internal Medicine
This article reports on two patients with predominantly hepatocellular liver injury that occurred during treatment with rivaroxaban. Both had massively elevated transaminase activity levels and hyperbilirubinaemia, and fulfilled the criteria of Hy's law.


MHRA responds to article in the Lancet that questions the authorisation of alteplase for acute ischaemic stroke

Medicines and Healthcare products Regulatory Agency
MHRA has responded to an article raising concerns about trial data for alteplase in ischaemic stroke. Although European regulators have concluded the benefit: risk balance is favourable, an expert working group will be set up to ensure all relevant evidence has been considered.



The above records have been identified by UKMi and feature in the NICE Medicines Awareness Service. Further details on this service can be found at: